[ad_1]
A new drug used to help prevent migraines in adults has just been approved by the US Food and Drug Administration, WAFB reports. The new drug is called Emgality and is used specifically to prevent migraines and not to treat the pain that they cause.
The current price of the drug is $ 575 per month. This price is expensive, but might be worth it for Americans suffering from persistent and debilitating migraines. Severe migraines can cause headache, vomiting, nausea and sensitivity to light. People with migraines usually have to stay out of work and are unable to perform their daily tasks as usual when they are affected.
The recommended dose of Emgality is 240 mg, administered in two separate injections. Injections are consecutive and should be administered monthly. The FDA intends that this is a drug that users can administer themselves. Similar to the way diabetic patients should administer their own insulin, patients or their caregivers will learn to give themselves the medication with the help of a pre-filled pen or syringe.
According to the National Headache Foundation, patients typically begin to show signs of migraines in early adolescence or at the age of 20 – and about 28 million Americans are affected.
#FDA approves new drug for the preventive treatment of migraine in adults: https://t.co/SPZk775P0D. pic.twitter.com/bij3UrcVY1
– FDA Drug Information (@FDA_Drug_Info) September 28, 2018
WebMD reports that Emgality is the third drug approved by the FDA that claims to prevent migraine headaches in adults. The drug's manufacturer, Eli Lily and Co., said that it should soon be available to the public.
"I've been living with migraine for over 30 years and I've seen the impact it has on your life, including your ability to do your daily activities," said Jill Dehlin, President. of the National Headache Foundation Patient Management Board, in a joint press release. "Those of us living with migraine have spent years hoping for new treatment options, and I'm grateful for the efforts of researchers, investigators, and clinical trial patients to help make this happen." possible."
The drug trial study included more than 1,700 people with episodic migraine. Those who received the drug reported fewer days of headaches than those who received the placebo. These results were replicated during a second trial.
A third trial involving more than 1,100 people with chronic migraine had similar positive results.
Side effects of the drug included pain, reactions, and redness at the injection site. There are other potential side effects, and anyone interested in trying the new medication should discuss treatment options – and potential side effects – thoroughly with their doctor.
[ad_2]
Source link
